russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2015-4-118-122russjcardiol-297Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWФАКТОРЫ ПАТОГЕНЕЗА ГЕСТАЦИОННОИ ГИПЕРТЕНЗИИFACTORS OF GESTATION HYPERTENSION PATHOGENESISКонышкоН. А.KonyshkoN. A.

доцент кафедры факультетской терапии

nkonyshko@yandex.ruМорозоваТ. Е.MorosovaT. E.

профессор, заведующая кафедрой клинической фармакологии и фармакотерапии

ГБОУ ВПО Смоленский государственный медицинский университет Минздрава России, СмоленскРоссияSBEI HPE Smolensk State Medical University of the Healthcare Ministry, SmolenskRussian FederationГБОУ ВПО Первый МГМУ им. И. М. Сеченова Минздрава России, Институт профессионального образования, Москва, РоссияРоссияSBEI HPE The First MSMU n.a. I.M. Sechenovof the Healthcare Ministry, Institute for Professional Education, Moscow, RussiaRussian Federation20152804201504118122Copyright © Конышко Н.А., Морозова Т.Е., 20152015Конышко Н.А., Морозова Т.Е.Konyshko N.A., Morosova T.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/297

В обзоре литературы представлены мнения учёных и результаты исследований относительно молекулярных механизмов патогенеза гестационной гипер-тензии и влияния социальных, психосоматических и анамнестических факторов на этапы формирования патологии.

The review focuses on the opinions of scientists and on the results of studies of molecular mechanisms in gestation hypertension pathogenesis as on the influence of social, psychosomatic and anamnestic factors on the stages of this pathology development.

гестационная гипертензия.gestation hypertensionReferencesThe Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens, 2007. 25:1105-87.The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens, 2007. 25:1105-87.Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux, 2008; 29 (4): 340-5.Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux, 2008; 29 (4): 340-5.Jauniaux E, Hempstock J, Greenwold N, et al. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal. Am. J. Pathol.2003; 162:115-25.Jauniaux E, Hempstock J, Greenwold N, et al. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal. Am. J. Pathol.2003; 162:115-25.Madazli R.,Yuksel M.A. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch. Gynecol. Obstet, 2014; 290(1): 53-7.Madazli R.,Yuksel M.A. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch. Gynecol. Obstet, 2014; 290(1): 53-7.Delmis J. Hypertension in pregnancy. Lijec. Vjesn2006; 128(11-12): 357-68.Delmis J. Hypertension in pregnancy. Lijec. Vjesn2006; 128(11-12): 357-68.Ajne G., Ahlborg G., Wolff K. Contribution of endogenous endothelin-1 to basal vascular tone during normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol, 2005; 193(1): 234-40.Ajne G., Ahlborg G., Wolff K. Contribution of endogenous endothelin-1 to basal vascular tone during normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol, 2005; 193(1): 234-40.George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens, 2011; 24(9): 964-9.George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens, 2011; 24(9): 964-9.Bellamy L, Casas JP, Hingorami AD. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 2007; 335: 974-82.Bellamy L, Casas JP, Hingorami AD. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ, 2007; 335: 974-82.Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux; 2008: 29(4): 340-5.Leeman M. Arterial hypertension in pregnancy. Rev. Med. Brux; 2008: 29(4): 340-5.Kaaja R, Delmis J. Predictors and risk factors of pre-eclampsia. Minerva Ginecol, 2008: 60(5): 421-9.Kaaja R, Delmis J. Predictors and risk factors of pre-eclampsia. Minerva Ginecol, 2008: 60(5): 421-9.Stepan H, Faber R,Wessel N. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab, 2006; 91: 2424-7.Stepan H, Faber R,Wessel N. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab, 2006; 91: 2424-7.Gadonski G, LaMarca BB, Sullivan E. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension, 2006; 48: 711 -6.Gadonski G, LaMarca BB, Sullivan E. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension, 2006; 48: 711 -6.LaMarca BB, Cockrell K. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension, 2005; 46: 82-6.LaMarca BB, Cockrell K. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension, 2005; 46: 82-6.Stepan H, Geipel A, Schwarz F Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol, 2008; 198(2): 175-6.Stepan H, Geipel A, Schwarz F Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol, 2008; 198(2): 175-6.Akolekar R, Etchegaray A, Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal. Diagn. Ther, 2009; 25(3): 320-7.Akolekar R, Etchegaray A, Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal. Diagn. Ther, 2009; 25(3): 320-7.De Vivo A, Baviera G. Endoglin, PIGF and sFlt-1 as markers for predicting pre-eclampsia. Ada Obstet Gynecol Scand, 2008; 87(8): 837-42.De Vivo A, Baviera G. Endoglin, PIGF and sFlt-1 as markers for predicting pre-eclampsia. Ada Obstet Gynecol Scand, 2008; 87(8): 837-42.Gilbert JS, Ryan MJ. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J. Physiol. Heart. Circ. Physiol, 2008; 294(2): 541-50.Gilbert JS, Ryan MJ. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J. Physiol. Heart. Circ. Physiol, 2008; 294(2): 541-50.Shah TJ, Leik CE, Walsh SW. Neutrophil infiltration and systemic vascular inflammation in obese women. Reprod. Sci, 2010; 17(2): 116-24.Shah TJ, Leik CE, Walsh SW. Neutrophil infiltration and systemic vascular inflammation in obese women. Reprod. Sci, 2010; 17(2): 116-24.Suzuki X Yamamoto T. Evaluation levels of cytokines in amniotic fluid of women with intrauterine infection in the early second trimester. Fetal. Diagn. Ther, 2006; 21(1): 45-50.Suzuki X Yamamoto T. Evaluation levels of cytokines in amniotic fluid of women with intrauterine infection in the early second trimester. Fetal. Diagn. Ther, 2006; 21(1): 45-50.Stepan H, Faber R. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab. 2006; 91: 2424-7.Stepan H, Faber R. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab. 2006; 91: 2424-7.Zhou CC, Ahmad S, Mil Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 2007; 100: 88-95.Zhou CC, Ahmad S, Mil Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res. 2007; 100: 88-95.Llinas M, Wallukat G. Agonistic autoantibodies to the AT1 receptor in a rat model of preeclampsia induced by chronic reductions in uterine perfusion pressure (RUPP). Hypertension 2005; 46: 884.Llinas M, Wallukat G. Agonistic autoantibodies to the AT1 receptor in a rat model of preeclampsia induced by chronic reductions in uterine perfusion pressure (RUPP). Hypertension 2005; 46: 884.SibaiB, DekkerG. Pre-eclampsia. Lancet 2005; 365: 785-99.SibaiB, DekkerG. Pre-eclampsia. Lancet 2005; 365: 785-99.Timmermans S, Jaddoe VW, Folic acid is positively associated with uteroplacental vascular resistance: The Generation R Study. Nutr. Metab. Cardiovasc. Dis 2009; 9: 1311-20.Timmermans S, Jaddoe VW, Folic acid is positively associated with uteroplacental vascular resistance: The Generation R Study. Nutr. Metab. Cardiovasc. Dis 2009; 9: 1311-20.Yajnik CS. Transmission of obesity-adiposity and related disorders from the mother to the baby. Ann. Nutr. Metab. 2014; 64: 8-17.Yajnik CS. Transmission of obesity-adiposity and related disorders from the mother to the baby. Ann. Nutr. Metab. 2014; 64: 8-17.Food and Drug Administration (USA) information on SafeFetus.com. http://www.safefetus. com/index.htm, 01.02.2014.Food and Drug Administration (USA) information on SafeFetus.com. http://www.safefetus. com/index.htm, 01.02.2014.

The authors declare that there are no conflicts of interest present.